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Abstract
Nemonoxacin (Taigexyn®), a novel C-8-methoxy non-fluorinated quinolone, 
has been approved for use in community-acquired pneumonia (CAP) in Taiwan 
(2014) and mainland China (2016). The FDA granted nemonoxacin ‘qualified 
infectious disease product’ and ‘fast-track’ designations for CAP and acute 
bacterial skin and skin structure infection in December 2013. It possesses a broad 
spectrum of bactericidal activity against typical and atypical respiratory patho-
gens. In particular, nemonoxacin has activity against resistant Gram-positive 
cocci, including penicillin-resistant Streptococcus pneumoniae and methicillin-
resistant Staphylococcus aureus. Oral nemonoxacin was compared with oral levo-
floxacin for efficacy and safety in three randomized, double-blinded, controlled 
Phase II–III clinical trials for the treatment of CAP. This article will review the 
microbiological profile of nemonoxacin against respiratory pathogens including 
S. pneumoniae and S. aureus, and microbiological outcome data from the three 
Phase II–III studies.
Keywords: community-acquired pneumonia, Gram-positive bacteria, levofloxacin, 
nemonoxacin, novel antimicrobial, resistant pathogens
1. Introduction
Lower respiratory tract infections (LRTIs), which include community-acquired 
pneumonia (CAP), are the fourth leading cause of death worldwide and the 
first leading cause of death in low-income countries, causing 3.0 million deaths 
worldwide in 2016 [1]. CAP is a common condition that causes a significant disease 
burden for the community, particularly in children younger than 5 years, the elderly 
and immunocompromised people [2].
Most studies about aetiology show that Streptococcus pneumoniae (S. pneu-
moniae) remains the most frequently isolated pathogen in CAP patients [3, 4]. The 
relative frequency of other typical pathogens include Haemophilus influenzae  
(H. influenzae), Moraxella catarrhalis (M. catarrhalis), and Klebsiella pneumoniae 
(K. pneumoniae) [1, 4, 5], as well as atypical organisms include Mycoplasma pneu-
moniae (M. pneumoniae), Chlamydia pneumoniae (C. pneumoniae), and Legionella 
pneumophila (L. pneumophila) [6–10]. Recently, methicillin-resistant Staphylococcus 
aureus (MRSA) is becoming a major pathogen of CAP and causing a rapidly fatal 
pneumonia characterized as pulmonary haemorrhage and rapid progression to 
respiratory failure [11–13]. The increasing prevalence of antibiotic resistance in 
CAP caused by penicillin-intermediate S. pneumoniae (PISP) and penicillin-resis-
tant S. pneumoniae (PRSP) are also of great concern [13].
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All patients with CAP should initially be treated with empirical antibiotic(s) 
because specific pathogens are typically not identified at the time that antibiotic 
therapy is initiated. Several retrospective studies have shown that pathogens 
were not isolated or identified in more than 50% of patients exhibiting clinical 
signs and symptoms of pneumonia [14–17]. Furthermore, increasing incidence 
of antibiotic resistance (major in penicillin, cephalosporin, and macrolide resis-
tance) observed in bacteria causing CAP has resulted in higher treatment failures 
and poorer medical outcomes for many patients with CAP [15]. A retrospective 
analysis indicated that the treatment failure of penicillin-based therapy was 
higher than that of fluoroquinolone-based therapy for CAP in an outpatient 
clinic basis [18]. The current recommendations for the management of commu-
nity acquired pneumonia indicated that monotherapy with a respiratory fluo-
roquinolone as an appropriate empirical treatment for adult CAP inpatients and 
complicated CAP outpatients with risk factors, more severe disease, or recent use 
of antibiotics [19].
Nemonoxacin (NEMO), a novel C-8-methoxy non-fluorinated quinolone, 
exhibits the bactericidal action by inhibition of the topoisomerase II (DNA 
gyrase) and topoisomerase IV which are required for bacterial DNA replication, 
repair, transcription, and recombination. The mechanism of action for quino-
lones, including NEMO, is different from that of aminoglycosides, beta-lactams, 
macrolides or tetracyclines; therefore, microorganisms resistant to these classes 
of drugs may be susceptible to NEMO. Resistance to fluoroquinolones occurs 
majorly by a mutation in DNA gyrase and/or topoisomerase IV genes, altered 
drug permeation through efflux transporter [20]. Mutations in two quinolone 
resistance-determining regions (QRDR) of genes encoding DNA gyrase (gyrA 
and gyrB) and topoisomerase IV (parC and parE) cause resistance to fluoro-
quinolones [21, 22]. However, bacteria resistance to NEMO only occurred when 
three different mutations was found in their QRDR genes [23]. Thus, NEMO 
has a higher barrier for generating resistant pathogens compared to other fluo-
roquinolones. In vitro resistance to NEMO develops slowly and difficultly via 
multiple-step mutations [24, 25].
NEMO has shown broad spectrum activity both in vitro and in vivo against 
Gram-positive and Gram-negative bacteria [25–30], particularly multi-drug 
resistant Gram-positive bacteria such as PRSP and MRSA. NEMO also exhibits 
potent antibacterial activity against Gram-negative bacteria and atypical patho-
gens such as H. influenzae, M. catarrhalis, M. pneumoniae, C. pneumoniae, and 
L. pneumophila in vitro [26, 31]. Oral NEMO (500 mg) has been approved for 
treatment of adult CAP patients in Taiwan (2014) and mainland China (2016) 
[32, 33]. In December 2013, the U.S. Food and Drug Administration (FDA) 
granted NEMO with ‘qualified infectious disease product (QIDP)’ and ‘fast-
track’ designations for CAP and acute bacterial skin and skin structure infection 
[34]. NEMO (intravenous formulation) also submitted its new drug application 
(NDA) in May 2017, and granted priority review by the China FDA in February 
2018 [35, 36].
An integrated analysis of one Phase III (registration number: NCT01529476) 
and two Phase II studies (registration numbers: NCT00434291 and NCT01537250) 
was conducted to compare the commercial dose of oral NEMO 500 mg vs. oral 
levofloxacin (LEVO) 500 mg for CAP treatment [37–39]. This article will review 
the integrated efficacy results of NEMO vs. LEVO against the common respira-
tory pathogens isolated from the three Phase II–III trials. LEVO was chosen as the 
comparator because it is commonly prescribed worldwide and it is recommended in 
guidelines for the treatment of CAP.
3Nemonoxacin (Taigexyn®): A New Non-Fluorinated Quinolone
DOI: http://dx.doi.org/10.5772/intechopen.88455
2. Materials and methods
2.1 Ethical approval
One Phase III study was conducted between March 2011 and August 2012 at 53 
centres in China and Taiwan [study number: TG-873870-C-4 (study C4)]; one Phase 
II study was conducted from August 2009 to August 2010 at 26 centres in China [study 
number: TG-873870-C-3 (study C3)]; the other Phase II study was conducted from 
December 2006 to September 2007 at 19 centres in the Republic of South Africa and 
Taiwan [study number: TG-873870-02 (study 02)]. Three studies were conducted 
in accordance with International Conference on Harmonization Guidelines, the 
Declaration of Helsinki, and the Good Clinical Practice. The protocols and sample 
informed consent form were approved by the Institutional Review Board of each 
participating study site. Written informed consent was provided by all patients or their 
legally authorized representatives prior to screening/study enrollment.
2.2 Study design
All three studies were designed as multicenter, randomized, double-blind, 
double-dummy, active comparator-controlled trials to assess the non-inferiority of 
NEMO vs. LEVO for the treatment of CAP in adult patients.
Eligible patients were randomized assigned in a 2:1 ratio to receive either NEMO 
500 mg or LEVO 500 mg in the phase III trial, and in a 1:1:1 ratio to receive either 
NEMO 500 mg or 750 mg, or LEVO 500 mg in the two phase II trials. All drugs 
were orally administered once daily for 7–10 days. To be evaluable, the test-of-cure 
(TOC) assessments had to occur between 7 and 21 days after administration of the 
last dose of study medication. This article will review the integrated efficacy results 
of three Phase II–III trials comparing the commercial dose of NEMO 500 mg vs. 
LEVO 500 mg for CAP treatment.
2.3 Eligibility criteria
Adult subjects were eligible if they had a clinical diagnosis of CAP (defined 
as fever, elevated white blood cell count, cough, purulent sputum, dyspnoea or 
tachypnoea, chest pain, pulmonary consolidation, etc.), had a chest radiograph 
demonstrating new or persistent/progressive infiltrate, and suitable for outpatient 
therapy with an oral antimicrobial agent.
Patients were excluded if they had any of the following conditions: severe CAP 
(e.g. requiring invasive endotracheal ventilation or vasoconstrictor due to septic 
shock), other pneumonia infection (e.g. hospital-acquired pneumonia, viral 
pneumonia, aspiration pneumonia), history of lung diseases (e.g. active tubercu-
losis, bronchiectasis, cystic fibrosis, lung abscess, lung cancer, post-obstructive 
pneumonia), history of hypersensitivity or allergic reactions to any quinolone, 
history of cardiac diseases (e.g. QTc prolongation, clinically significant abnormality 
on a 12-lead electrocardiogram at screening), clinically significant renal, hepatic 
or mental disease, malabsorption syndrome, and received prohibited medications 
prior enrollment (e.g. other investigational drug, systemic antibacterial agent, 
chemotherapeutic agents or oncolytics).
Subjects could be withdrawn from the study at any time, for any reason, and 
without prejudice to further treatment. The criteria for enrollment were to be 
followed explicitly. If a patient who did not meet enrollment criteria was inadver-
tently enrolled, that patient was withdrawn from the study. An exception could 
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have been granted in rare circumstances where there was a compelling safety or 
ethical reason to allow the patient to continue. In these rare cases, the Investigator 
was required to obtain documented approval from Sponsor to allow the subject to 
continue in the study.
2.4 Efficacy assessment
Clinical response at the TOC visit was the primary efficacy endpoint for the 
three CAP studies. Clinical response was defined as cure (complete resolution 
or improvement of all pneumonia-related signs and symptoms that existed 
during enrollment, with chest radiographs improved or not worse, no further 
antibiotic therapy required, and no new sign and symptoms occurred), failure 
(persistence or worsening of sign and symptoms of pneumonia, additional 
treatment with a non-study antibiotic for pneumonia, or progression of chest 
radiograph abnormalities) or unevaluable (lost to follow-up or withdrew 
consent which made it lost post-treatment information, failed to complete at 
least 3 days of treatment, or had an infection other than pneumonia judged by 
the investigator).
Microbiological response at the TOC visit was the secondary efficacy endpoint 
for the three CAP studies. Microbiological success was defined as eradication (the 
baseline pathogen was absent) and presumed eradication (if an adequate source 
specimen was not available to culture, but the patient was assessed as clinically 
cured). Microbiological failure was defined as persistence and presumed persis-
tence of the baseline pathogen.
2.5 Microbiological evaluations
Baseline bacterial cultures were taken from the primary site of infection (e.g. 
sputum expectoration), together with 2 sets of blood cultures obtained within 24 h 
before patients received the 1st dose of study drugs.
Sputum samples were collected by expectoration after deep coughing. Fresh 
specimens collected under the supervision of the investigator were immediately 
transported to a local laboratory for Gram stain. Cultures were only performed on 
specimens if the Gram stain revealed <10 squamous epithelial cells and >25 leuko-
cytes per low-power field. All isolates identified at the local laboratory from such 
specimens were then sent to the central laboratory for re-identification and suscep-
tibility testing using CLSI methodology. Only the central laboratory microbiology 
results were utilized in the database. The only exception was if a local laboratory 
specimen had become unavailable. MICs of NEMO and LEVO were determined for 
all isolates.
Serology tests for M. pneumoniae, C. pneumoniae, and L. pneumophila were 
performed at both baseline and TOC visits. Urine samples were also collected to 
identify L. pneumophila by antigen testing at the baseline visit.
2.6 Statistics
Non-inferiority (NI) of NEMO to LEVO was evaluated for clinical response 
by using 2-sided 95% confidence interval (CI) for the true difference in clini-
cal cure rate (NEMO minus LEVO), with clinical cure or failure determined at 
the TOC visit. NI was concluded if the lower limit of the 2-sided 95% CI was 
not lower than −10% for the phase III study (lower limit of 95% CI ≥ −10%), 
and not lower than −15% for the two phase II studies (lower limit of 95% 
CI ≥ −15%).




The clinical responses at the TOC visit for NEMO 500 mg compared to LEVO 
500 mg are outlined in Table 1. The integrated analysis of clinical cure rate for 
NEMO was 93.0% compared with 91.9% for LEVO.
All three studies met its clinical endpoint by confirming the non-inferiority 
of NEMO 500 mg compared with LEVO 500 mg. In the primary population with 
evaluable assessment at TOC visit, the clinical cure rates for NEMO and LEVO were 
94.3% (300/318) and 93.5% (143/153), respectively, in study C4; 93.3% (56/60) 
and 88.5% (46/52), respectively, in study C3; and 87.0% (67/77) and 91.1% (72/79), 
respectively, in study 02. The treatment differences (95% CI) between NEMO and 
LEVO were 0.9% (−3.8%, 5.5%) in study C4, 4.9% (−5.9%, 15.6%) in study C3, and 
−4.1% (−13.9%, 5.7%) in study 02. Thus, in the three studies, NEMO was found 
to be non-inferior to LEVO because the lower limit of the 95% CI of the treatment 
difference was ≥ −10% in the phase III study and ≥ −15% in both phase II studies. 
Non-inferiority of NEMO 500 mg to LEVO 500 mg was demonstrated.
3.2 Microbiological response
3.2.1 Overall recovery rate
The overall recovery rate of pathogens (typical and atypical combined) in all 
randomized patients was 57.0% (504/989). This included pathogens identified in 









Curea 423 (93.0%) 261 (91.9%) —
Failure 32 (7.0%) 23 (8.1%)
Unevaluable 22 (−) 18 (−)
Phase III Study-C4
Primary populationb Curea 300 (94.3%) 143 (93.5%) 0.9 (−3.8, 5.5)
Failure 18 (5.7%) 10 (6.5%)
Unevaluable 10 (−) 7 (−)
Phase II Study-C3
Primary populationb Curea 56 (93.3%) 46 (88.5%) 4.9 (−5.9,15.6)
Failure 4 (6.7%) 6 (11.5%)
Unevaluable 0 (−) 0 (−)
Phase II Study-02
Primary populationb Curea 67 (87.0%) 72 (91.1%) −4.1 (−13.9,5.7)
Failure 10 (13.0%) 7 (8.9%)
Unevaluable 12 (−) 11 (−)
aClinical cure rate = 100 × number of patients with clinical cure/(number of patients with clinical cure + number of 
patients with clinical failure). Unevaluable response was excluded.
bPrimary populations were modified intention-to-treat (mITT), full analysis set (FAS), and intention-to-treat (ITT) 
for TG-873870-C4, TG-873870-C3, and TG-873870-02 studies, respectively [35–37].
Table 1. 
Clinical response at TOC in primary population.
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appropriate sputum specimen, blood, or other test such as urinary antigen test and 
atypical pathogen serology testing. The recovery rate for typical pathogens was 29.3% 
(290/989). These results were consistent with those observed in other CAP studies 
[38–42]. The most commonly identified pathogens in all randomized patients were K. 
pneumoniae, S. pneumoniae, Haemophilus species, and S. aureus (Figure 1).
3.2.2 Microbiological responses to individual pathogens
The per-pathogen responses of NEMO 500 mg and LEVO 500 mg for the most 
prevalent pathogens are outlined in Table 2. High clinical and microbiological 
response rates were achieved against the common CAP pathogens, with similar 
success rates between the two treatment groups.
The microbiological responses were evaluated in the primary populations who 
had at least one typical bacterial pathogen identified at baseline from an appropri-
ate specimen. Microbiological eradication and presumed eradication were con-
sidered to be success responses. The microbiological success rates for the common 
baseline CAP pathogens (NEMO vs. LEVO) were 95.6% (22/23) vs. 90.0% (18/20) 
for S. pneumoniae, 95.2% (20/21) vs. 88.9% (8/9) for S. aureus, 92.9% (39/42) 
vs. 86.1% (31/36) for K. pneumoniae, and 90.7% (39/43) vs. 91.3% (21/23) for 
Haemophilus species.
Among the S. pneumoniae isolates, four were penicillin non-susceptible (PRSP 
and PISP), with three isolates identified in the NEMO group and one isolate in 
the LEVO group. The microbiological responses for penicillin non-susceptible S. 
pneumoniae were all success for both groups.
As expected in CAP, the isolation of MRSA was rare, with only 4 isolates iden-
tified in the NEMO group. Three out of four patients infected with MRSA had 
successful responses after receiving NEMO.
Overall, the clinical and microbiological responses for the most commonly 
identified pathogens were almost concordant. High clinical cure rates were achieved 
Figure 1. 
Identification and prevalence of baseline pathogens in three CAP studies.
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against not only typical bacteria but also atypical pathogens after NEMO treatment, 
with 92.8% (90/97), 95.7% (22/23), and 90.5% (19/21) for M. pneumoniae,  
C. pneumoniae, and L. pneumophila, respectively.
3.2.3 Antimicrobial susceptibility
The susceptibility of baseline pathogens isolated from the three CAP studies 
are outlined in Table 3. All isolates of S. pneumoniae, including PRSP and LEVO-
resistant strains, were inhibited by NEMO at concentrations of ≤1 mg/L. The MIC90 
for S. pneumoniae were 0.125 mg/L for NEMO and 1 mg/L for LEVO.
NEMO was active against S. aureus, with MIC90 of 0.25 mg/L compared with 
an MIC90 of 2 mg/L for LEVO. Among the S. aureus, 5 isolates were MRSA, with 
MIC ranges of 0.03–1 mg/L for NEMO and 0.12–32 mg/L for LEVO. All isolates 
of S. aureus, including MRSA, were inhibited by NEMO at concentrations of 
≤1 mg/L.
The in vitro activity of NEMO was comparable to that of LEVO against Gram-
negative bacteria. But for Gram-positive bacteria including MRSA, the MICs of 
NEMO were 8-fold lower than that of LEVO, supporting its utility in the treatment 
of patients with CAP.










Streptococcus pneumoniae 22/24 (91.7%) 19/20 (95.0%) 22/23 (95.6%) 18/20 (90.0%)
PRSP 1 (100.0%) 1 (100.0%) 1 (100.0%) 1 (100.0%)
PISP 2 (100.0%) — 2 (100.0%) —
Staphylococcus aureus 20/21 (95.2%) 8/9 (88.9%) 20/21 (95.2%) 8/9 (88.9%)
MRSA 3/4 (75.0%) — 3/4 (75.0%) —
Gram-negative bacteria
Klebsiella pneumoniae 40/42 (95.2%) 32/36 (88.9%) 39/42 (92.9%) 31/36 (86.1%)
Haemophilus species 39/43 (90.7%) 21/23 (91.3%) 39/43 (90.7%) 21/23 (91.3%)
Escherichia coli 5/5 (100.0%) 1/1 (100.0%) 5/5 (100.0%) 1/1 (100.0%)
Moraxella catarrhalis 2/2 (100.0%) 3/3 (100.0%) 2/2 (100.0%) 3/3 (100.0%)
Pseudomonas aeruginosa 6/7 (85.7%) 5/5 (100.0%) 6/7 (85.7%) 4/5 (80.0%)
Acinetobacter baumannii 5/5 (100.0%) 1/1 (100.0%) 5/5 (100.0%) 1/1 (100.0%)
Atypical pathogens
Mycoplasma pneumoniae 90/97 (92.8%) 63/66 (95.5%) — —
Chlamydia pneumoniae 22/23 (95.7%) 16/16 (100.0%) — —
Legionella pneumophila 19/21 (90.5%) 8/8 (100.0%) — —
aClinical cure rate = 100 × number of patients with clinical cure/(number of patients with clinical cure + number of 
patients with clinical failure). Unevaluable response was excluded.
bMicrobiological success rate  =  100  ×  number of patients with success response/(number of patients with success 
response + number of patients with failure response). Unevaluable response was excluded.
Table 2. 




Efficacy data reported herein from the individual and integrated analyses of 
the three CAP trials demonstrate that oral NEMO 500 mg administered once daily 
for 7–10 days is an efficacious treatment for adult CAP. Non-inferiority of NEMO 
500 mg to LEVO 500 mg, a widely used agent in the clinical setting, was demon-
strated in the three CAP studies. NEMO was effective in eradicating the typical 
pathogens associated with CAP, including high cure rates for atypical pathogens. 
Furthermore, the in vitro activity of NEMO against bacterial pathogens isolated 
from patients enrolled in the CAP clinical trials demonstrated a susceptibility 
profile that supports its utility in the treatment of patients with CAP.
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